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‐Homogenous mode of action for oncogenes within cancer cells.
‐Brief inactivation of oncogenes can cause cancer remission in model systems.
‐However, unfortunately, the therapies based on this cancer model fail to eradicate tumours
in humans.
Current model of cancer
Do the oncogenes have a mode of action that is not homogeneous
throughout the cancer cell population?
Classical model for the role of human cancer gene defects 
in tumour cell fate specification
Traditionally, the human cancer genetic defects have been thought to act on cells already committed
to a differentiation program, in such a way that the tumoural phenotype is derived from that of the initial differentiated target cell
Alternative model for the role of human cancer gene 
defects in tumour cell fate specification
Alternative view in which the oncogenic lesion acts on stem/progenitor cells by imposing 
a given, oncogene‐specific, tumour‐differentiated cell fate.









The CSC hypothesis is in good agreement with the interpretation of oncogenesis presented
in slide 4.






Vicente-Dueñas et al. The EMBO Journal 2013
In vivo experimental model of tumoral stem cell 
reprogramming
To be able to demonstrate this lack of homogeneity in the mode of action of oncogenes throughout the
biological history of the tumor, it would be necessary to dissect and isolate the function that the oncogene
is playing at the earliest stages of the disease, at the level of the cell‐of‐origin
Written on his blackboard at time of his death, in 1988
Human Cancer tissue
Genetic defect is present in both CSC 
and differentiated tumor cells
In vivo experimental model of
tumoural stem cell reprogramming
Genetic defect is only present in CSC
?
Might cancer stem cells initially arise thorugh a reprogramming-like mechanism?
To be able to demonstrate this lack of homogeneity in the mode of actions of oncogenes throughout the biological history of the tumour.
This still unexplored possibility would have major implications for our understanding of the genesis and treatment of cancer








Bulk Cancer Cells (Myeloid cells) without oncogene
Tumoral stem cell reprogramming in malignancies
supposed to originate in HSC
EMBO J. 28(1):8-20 (2009).
Cell Cycle 8:1314-1318 (2009)
N Engl J Med. 360(3):297-299 (2009)
1- Proof of principle experiment
2- Chronic myeloid leukemia (CML) stem cells are not oncogene addicted and 
the therapies that biochemically target BCR-ABL do not eliminate them (CML stem 
cells).
3-First animal model aniticipating human clinical results in the CSC field
4-Results were confirmed in human patients two years later
Tumoral stem cell reprogramming in malignancies
supposed to originated HSC
EMBO J. 28(1):8-20 (2009).
Cell Cycle 8:1314-1318 (2009)
N Engl J Med. 360(3):297-299 (2009)
Can this hypothesis be extrapolated to other malignancies?
Contribution of MafB to multiple myeloma biology?
Cell Cycle. 2013;12(1):122-32.
EMBO J. 2012 Sep 12;31(18):3704-17
retrodifferentiation
transdifferentiation
Incurable neoplasm characterized by the accumulation of
malignant plasma cells
human MM pathology: 
- Bone marrow plasmacytosis.
- Serum accumulation of monoclonal immunoglobulin.
- Amyloid Deposits. 
- Kidney damage.
- Osteolytic lesions.
- Bone marrow failure.
Human multiple myeloma
Cancer Cell-of-Origin and Reprogramming in Multiple Myeloma







Accepted Stem Cell-based tumor:
Chronic Myeloid Leukemia
Accepted Differentiated Cell-based tumor:
Multiple Myeloma
EMBO J (2009) 28:8-20; Cell Cycle (2009) 8:1314-1318 EMBO J. 31(18):3704-17 (2012); Cell Cycle 11(20):3896-900 (2012 )
Human MM disease has not been modelled in mice when human oncogenes have been targeted 
to the mouse B-cell compartment
Multiple myeloma as a result of tumoral stem cell reprogramming
The results demonstrate that HS/P-Cs can be reprogrammed to terminally differentiated tumor plasma cells by a defined factor (MafB). 




EMBO J. 2012 Sep 12;31(18):3704-17
Proc Natl Acad Sci U S A. 2012;109(26):10534-9
Cancer Cell-of-Origin and Reprogramming in MALT1 lymphoma




Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10534-9
Human MALT disease has not been modelled in mice when human oncogenes have been targeted 
to the mouse B-cell compartment
Typical histopathological picture: 
Tumors involved multiple extranodal sites, including the spleen, small intestine, salivary glands, kidneys, lungs, 
liver, stomach and ocular adnexa. 
In the epithelial tissues, the cells infiltrated the  epithelium and formed lymphoepithelial lesions.
Intestinal human MALT lymphomas and human-like mouse MALT lymphomas 
showed similar histopathological pictures including
typical lymphoepithelial lesions
MALT1 lymphoma as a result of tumoral stem cell reprogramming
Cell Cycle. 2013;12(1):122-32.
EMBO J. 2012 Sep 12;31(18):3704-17
Tumour stem cell reprogramming and therapeutic implications





Stem cell reprogramming (where the maintenance of oncogene expression is not critical for the 
generation of differentiated tumor cells) seems to be a common intrinsic mechanism for many type 
of cancers, and this should change our understanding of the means by which “hallmark cancer 
capabilities” are acquired.
This conceptualization of tumour reprogramming by oncogenes will change the way we investigate 
and treat cancer in the years to come:
1- These discoveries introduce a new perspective on oncogenic transformation: certain oncogenes
may act as “passengers” to reprogram tissue-specific stem/progenitors cells into a malignant 
cancer stem cell state.
2- This discovery will also force us to explore and answer fundamental questions in cancer biology, 
such as how cells acquire and maintain their tumour differentiation states (oncogenes work as a 
new type of gene-target cell interaction in which oncogene exposure targets the epigenome to 
induce cancer development).
3- To add new layers of complexity, the effect of such epigenetic reprogramming may remain 
dormant until engaged in response to later adult events (genetics and/or environmental).
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